Lamivudina Viatris (Lamivudine)

Lamivudine is a nucleoside analogue that mimics the natural building block deoxycytidine. It is phosphorylated inside cells and then incorporated by viral reverse transcriptase into the growing DNA chain. Because it lacks a 3′‑hydroxyl group, it prevents further elongation of the viral DNA, leading to chain termination and inhibition of viral replication for both HIV and hepatitis B.

The specific dose of Lamivudina Viatris is determined by the prescribing healthcare professional based on the patient’s clinical condition, weight, renal function, and treatment regimen. Standard dosing recommendations exist in clinical guidelines, but the exact amount and frequency should be set by the prescriber and not inferred from product information alone.

Safety data for lamivudine in pregnancy and lactation are limited. The drug may be prescribed during pregnancy only when the potential benefit to the mother outweighs any possible risk to the fetus, and similar caution applies to breastfeeding. Clinicians should evaluate individual circumstances and follow local regulatory guidance.

To order Lamivudina Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often compared with emtricitabine, another NRTI with a similar safety profile and potency. Both drugs are used in combination regimens, but lamivudine has a longer history of use in hepatitis B treatment, whereas emtricitabine is more commonly paired with tenofovir in HIV fixed‑dose combinations.

Lamivudina Viatris should be stored at room temperature, preferably below 25 °C. Keep the tablets in the original packaging to protect them from moisture and light. Do not store in a bathroom or near a heat source, and keep out of reach of children.

Lamivudina Viatris is taken orally as a tablet. The tablet should be swallowed whole with a glass of water and can be taken with or without food, unless otherwise directed by the prescriber. Consistency in timing helps maintain steady drug levels.

The most serious adverse events linked to lamivudine include lactic acidosis, severe hepatotoxicity, and hypersensitivity reactions such as Stevens‑Johnson syndrome. These conditions are rare but require immediate medical attention if symptoms such as unexplained fatigue, abdominal pain, jaundice, rash, or blistering develop.

Lamivudina Viatris should be avoided in individuals with a known hypersensitivity to lamivudine or any of the tablet’s excipients. Patients with severe hepatic impairment or uncontrolled liver disease should not use the product without careful medical supervision. Pregnant or breastfeeding women should only use it when clearly indicated by a healthcare professional.